Your session is about to expire
← Back to Search
Study Summary
This trial looks at DSP-0390, a new drug, as a possible treatment for people with a certain type of brain tumor that has come back.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am mostly able to care for myself and carry out daily activities.I haven't had treatments targeting blood vessel growth in the last 3 months.I have not had lung inflammation or disease in the last 6 months.I have recovered from previous cancer treatment side effects.My blood counts and organ functions are within the required ranges.My corticosteroid dose has been stable or decreasing for the last 5 days.I haven't had recent major surgery, brain bleeding, recent chemo or radiotherapy, and I'm not using prohibited meds or Optune.I have an active eye condition affecting my retina.My cancer has spread to multiple areas, including the brain's lining or beyond.I do not have significant heart issues, swallowing disorders, or severe digestive conditions.I have not had another type of cancer in the last 2 years.My epilepsy medication dose has been stable and I've had no seizures for 14 days.I haven't had major surgery or significant heart disease issues in the last 4 weeks.
- Group 1: Single arm DSP-0390
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How extensive is the subject population for this medical trial?
"Affirmative. Data hosted on clinicaltrials.gov verifies that recruitment for this medical trial is currently ongoing; the study was first announced in September 2021, with its information last refreshed during October 2022. The research requires 70 test subjects to be sourced from 6 separate centres."
Are there currently any opportunities for patients to participate in this medical trial?
"This clinical trial, which is documented on clinicaltrials.gov and was initially posted on September 8th 2021, is actively looking for participants. In fact the study has been updated most recently in October 28th 2022."
What are the objectives of this research endeavor?
"According to the trial's sponsor, Sumitomo Dainippon Pharma Oncology, Inc., this research project seeks to measure its primary outcome over a 6-month timeframe by performing radiologic examinations at 8 week intervals. The primary objective of these assessments is ascertaining the safety of the Recommended Phase 2 Dosage through gauging toxicity and adverse events. Additionally, secondary outcomes such as PK profiles for Racc, AUC and Cmax will be studied."
How many facilities are managing this experiment?
"Washington University School of Medicine in Saint Louis, Missouri, Huntsman Cancer Institute, University of Utah in Salt Lake City, Utah and Columbia University in New york, New York are just some of the clinical trial sites enrolling patients. There are 6 more locations that are also participating."
Share this study with friends
Copy Link
Messenger